ArticleCancer control : journal of the Moffitt Cancer Center
Factors Associated With Cause-specific Mortality in Older Patients With Advanced NSCLC Treated With PD-1 Inhibitors: A U.S. Population-based Cohort Study.
Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
IntroductionDespite improved outcomes with PD-1 inhibitors (PD-1i) in advanced non-small cell lung cancer (NSCLC), the determinants of cancer-, cardiovascular disease (CVD)-, and other-cause mortality remain poorly characterized in older adults. This study applies competing-risks methods to estimate cause-specific mortality and to identify predictors for each cause in this population.MethodsA retrospective cohort study was conducted using the 2014-2019 SEER-Medicare linked database, including patients aged 65 years or older with advanced NSCLC who received PD-1i (nivolumab or pembrolizumab). Mortality outcomes included deaths from CVD, NSCLC, other cancers, and other diseases. Predictors included treatment-related factors (e.g., PD-1i type), demographic factors (e.g., age, sex), socioeconomic status (e.g., Medicaid dual eligibility), cancer-related factors (e.g., NSCLC stage), and comorbidities (e.g., congestive heart failure [CHF]). Competing risk analyses were performed using the Fine-Gray model, with cause-specific Cox models for sensitivity analyses.ResultsAmong 5076 patients, 68.36% received nivolumab and 31.64% received pembrolizumab. Of 3746 deaths, most were from NSCLC (85.34%), while 2.80% were from CVD. No significant difference in CVD mortality risk was observed between the two PD-1i (sub-distribution HR [sHR] = 1.08; 95% CI: 0.63-1.84), but NSCLC mortality was associated with a lower risk in the pembrolizumab group (sHR = 0.67; 95% CI: 0.60-0.74) compared to the nivolumab group. A history of CHF (sHR = 2.10; 95% CI: 1.37-3.21) and Medicaid dual eligibility (sHR = 2.70 vs private insurance; 95% CI: 1.28-5.56) were associated with increased CVD mortality. NSCLC mortality was higher in Stage IV/distant than in Stage IIIB/regional (sHR = 1.24; 95% CI: 1.13-1.35) and males (sHR = 1.11; 95% CI: 1.03-1.20).ConclusionsThese results highlight the potential value of integrated cardio-oncology models and strategies addressing socioeconomic inequities among older adults receiving PD-1i. However, conclusions should be tempered by the SEER-Medicare data structure, including lack of biomarker information and restricted applicability to younger or non-Medicare populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.